Gilead is in discussions with pharmaceutical and chemical manufacturing companies to license the rights to make remdesivir in Europe, Asia and some developing countries through at least 2022.
It is also working with India and Pakistan to grant them long-term licenses to sell generic versions of remdesivir.
Gilead said it is in talks with the Medicines Patent Pool, a United Nations-backed nonprofit organization, to license remdesivir to low-income countries.
Public health experts have predicted high global demand for remdesivir, according to the Journal, as preliminary data have shown it is effective in shortening the length of illness from COVID-19 infection.
Gilead hasn’t priced remdesivir yet, but has promised to make it accessible globally.
Read the full article here.
More articles on pharmacy:
FDA clarifies relaxed compounding rules for pharmacies
Gilead gets FDA emergency use authorization for remdesivir
AmerisourceBergen offers to buy Walgreens’ drug wholesaling division
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
